ENANTA PHARMACEUTICALS, INC Investing Cash Flow
ENANTA PHARMACEUTICALS, INC (ENTA) reported Investing Cash Flow of -$21.35 million for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-12
- ENANTA PHARMACEUTICALS, INC net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $14.01M.
- ENANTA PHARMACEUTICALS, INC net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $11.94M.
- ENANTA PHARMACEUTICALS, INC net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$47.30M, a 168.64% decline year-over-year.
- ENANTA PHARMACEUTICALS, INC net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $2.30M, a 87.96% decline year-over-year.
- ENANTA PHARMACEUTICALS, INC net cash provided by (used in) investing activities for fiscal 2025 was $40.35M, a 30.72% decline from fiscal 2024.
- ENANTA PHARMACEUTICALS, INC net cash provided by (used in) investing activities for fiscal 2024 was $58.23M.
- ENANTA PHARMACEUTICALS, INC net cash provided by (used in) investing activities for fiscal 2023 was -$53.58M, a 197.60% decline from fiscal 2022.
- ENANTA PHARMACEUTICALS, INC net cash provided by (used in) investing activities for fiscal 2022 was $54.90M, a 48.41% increase from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $14.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-12 | $25.95M derived: sum of 2 quarters · filed 2026-08-12 | -$21.35M 10-Q · filed 2026-08-12 | -$19.05M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $11.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-13 | -$35.36M 10-Q · filed 2026-05-13 | -$33.06M derived: sum of 3 quarters · filed 2026-05-13 | -$59.54M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$47.30M 10-Q · filed 2026-02-11 | -$45.00M derived: sum of 2 quarters · filed 2026-02-11 | -$71.48M derived: sum of 3 quarters · filed 2026-08-12 | -$75.85M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-09-30 | $2.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-19 | -$24.19M derived: sum of 2 quarters · filed 2026-08-12 | -$28.56M derived: sum of 3 quarters · filed 2026-08-12 | $40.35M 10-K · filed 2025-11-19 |
| 2025-06-30 | -$26.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-12 | -$30.85M derived: sum of 2 quarters · filed 2026-08-12 | $38.05M 10-Q · filed 2026-08-12 | $57.12M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$4.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-13 | $64.53M 10-Q · filed 2026-05-13 | $83.61M derived: sum of 3 quarters · filed 2026-05-13 | $77.26M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $68.90M 10-Q · filed 2026-02-11 | $87.98M derived: sum of 2 quarters · filed 2026-02-11 | $81.63M derived: sum of 3 quarters · filed 2026-02-11 | $140.25M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-09-30 | $19.07M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-19 | $12.73M derived: sum of 2 quarters · filed 2025-11-19 | $71.35M derived: sum of 3 quarters · filed 2025-11-19 | $58.23M 10-K · filed 2025-11-19 |
| 2024-06-30 | -$6.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-08-13 | $52.28M derived: sum of 2 quarters · filed 2025-08-13 | $39.16M 10-Q · filed 2025-08-13 | $51.00M derived: sum of 4 quarters · filed 2025-11-19 |
| 2024-03-31 | $58.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-05-14 | $45.51M 10-Q · filed 2025-05-14 | $57.34M derived: sum of 3 quarters · filed 2025-11-19 | -$88.41M derived: sum of 4 quarters · filed 2025-11-19 |
| 2023-12-31 | -$13.12M 10-Q · filed 2025-02-12 | -$1.28M derived: sum of 2 quarters · filed 2025-11-19 | -$147.03M derived: sum of 3 quarters · filed 2025-11-19 | -$100.26M derived: sum of 4 quarters · filed 2025-11-19 |
| 2023-09-30 | $11.84M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-19 | -$133.91M derived: sum of 2 quarters · filed 2025-11-19 | -$87.15M derived: sum of 3 quarters · filed 2025-11-19 | -$53.58M 10-K · filed 2025-11-19 |
| 2023-06-30 | -$145.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-08-07 | -$98.98M derived: sum of 2 quarters · filed 2024-08-07 | -$65.41M 10-Q · filed 2024-08-07 | -$37.18M derived: sum of 4 quarters · filed 2024-11-27 |
| 2023-03-31 | $46.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-05-08 | $80.33M 10-Q · filed 2024-05-08 | $108.56M derived: sum of 3 quarters · filed 2024-11-27 | $124.78M derived: sum of 4 quarters · filed 2024-11-27 |
| 2022-12-31 | $33.57M 10-Q · filed 2024-02-08 | $61.80M derived: sum of 2 quarters · filed 2024-11-27 | $78.02M derived: sum of 3 quarters · filed 2024-11-27 | $42.97M derived: sum of 4 quarters · filed 2024-11-27 |
| 2022-09-30 | $28.23M derived: 10-K 12 month − 10-Q 9 month · filed 2024-11-27 | $44.45M derived: sum of 2 quarters · filed 2024-11-27 | $9.40M derived: sum of 3 quarters · filed 2024-11-27 | $54.90M 10-K · filed 2024-11-27 |
| 2022-06-30 | $16.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-08-08 | -$18.84M derived: sum of 2 quarters · filed 2023-08-08 | $26.67M 10-Q · filed 2023-08-08 | $99.35M derived: sum of 4 quarters · filed 2023-11-22 |
| 2022-03-31 | -$35.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-05-09 | $10.45M 10-Q · filed 2023-05-09 | $83.13M derived: sum of 3 quarters · filed 2023-11-22 | $39.42M derived: sum of 4 quarters · filed 2023-11-22 |
| 2021-12-31 | $45.50M 10-Q · filed 2023-02-08 | $118.18M derived: sum of 2 quarters · filed 2023-11-22 | $74.48M derived: sum of 3 quarters · filed 2023-11-22 | $99.94M derived: sum of 4 quarters · filed 2023-11-22 |
| 2021-09-30 | $72.68M derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-22 | $28.98M derived: sum of 2 quarters · filed 2023-11-22 | $54.44M derived: sum of 3 quarters · filed 2023-11-22 | $36.99M 10-K · filed 2023-11-22 |
| 2021-06-30 | -$43.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-08-08 | -$18.25M derived: sum of 2 quarters · filed 2022-08-08 | -$35.69M 10-Q · filed 2022-08-08 | -$33.19M derived: sum of 4 quarters · filed 2022-11-23 |
| 2021-03-31 | $25.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-05-09 | $8.01M 10-Q · filed 2022-05-09 | $10.52M derived: sum of 3 quarters · filed 2022-11-23 | $37.30M derived: sum of 4 quarters · filed 2022-11-23 |
| 2020-12-31 | -$17.45M 10-Q · filed 2022-02-10 | -$14.94M derived: sum of 2 quarters · filed 2022-11-23 | $11.84M derived: sum of 3 quarters · filed 2022-11-23 | $39.59M derived: sum of 4 quarters · filed 2022-11-23 |
| 2020-09-30 | $2.50M derived: 10-K 12 month − 10-Q 9 month · filed 2022-11-23 | $29.28M derived: sum of 2 quarters · filed 2022-11-23 | $57.03M derived: sum of 3 quarters · filed 2022-11-23 | $19.83M 10-K · filed 2022-11-23 |
| 2020-06-30 | $26.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-08-09 | $54.53M derived: sum of 2 quarters · filed 2021-08-09 | $17.33M 10-Q · filed 2021-08-09 | -$34.88M derived: sum of 4 quarters · filed 2021-11-24 |
| 2020-03-31 | $27.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-05-10 | -$9.45M 10-Q · filed 2021-05-10 | -$61.66M derived: sum of 3 quarters · filed 2021-11-24 | -$76.51M derived: sum of 4 quarters · filed 2021-11-24 |
| 2019-12-31 | -$37.20M 10-Q · filed 2021-02-09 | -$89.41M derived: sum of 2 quarters · filed 2021-11-24 | -$104.26M derived: sum of 3 quarters · filed 2021-11-24 | -$102.93M derived: sum of 4 quarters · filed 2021-11-24 |
| 2019-09-30 | -$52.21M derived: 10-K 12 month − 10-Q 9 month · filed 2021-11-24 | -$67.06M derived: sum of 2 quarters · filed 2021-11-24 | -$65.73M derived: sum of 3 quarters · filed 2021-11-24 | -$86.66M 10-K · filed 2021-11-24 |
| 2019-06-30 | -$14.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-08-10 | -$13.53M derived: sum of 2 quarters · filed 2020-08-10 | -$34.46M 10-Q · filed 2020-08-10 | -$42.41M derived: sum of 4 quarters · filed 2020-11-25 |
| 2019-03-31 | $1.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-05-11 | -$19.61M 10-Q · filed 2020-05-11 | -$27.56M derived: sum of 3 quarters · filed 2020-11-25 | -$59.02M derived: sum of 4 quarters · filed 2020-11-25 |
| 2018-12-31 | -$20.93M 10-Q · filed 2020-02-10 | -$28.88M derived: sum of 2 quarters · filed 2020-11-25 | -$60.34M derived: sum of 3 quarters · filed 2020-11-25 | -$53.88M derived: sum of 4 quarters · filed 2020-11-25 |
| 2018-09-30 | -$7.95M derived: 10-K 12 month − 10-Q 9 month · filed 2020-11-25 | -$39.41M derived: sum of 2 quarters · filed 2020-11-25 | -$32.95M derived: sum of 3 quarters · filed 2020-11-25 | -$35.40M 10-K · filed 2020-11-25 |
| 2018-06-30 | -$31.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-08-09 | -$25.00M derived: sum of 2 quarters · filed 2019-08-09 | -$27.45M 10-Q · filed 2019-08-09 | -$42.35M derived: sum of 4 quarters · filed 2019-11-27 |
| 2018-03-31 | $6.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-05-10 | $4.01M 10-Q · filed 2019-05-10 | -$10.89M derived: sum of 3 quarters · filed 2019-11-27 | |
| 2017-12-31 | -$2.45M 10-Q · filed 2019-02-08 | -$17.35M derived: sum of 2 quarters · filed 2019-11-27 | ||
| 2017-09-30 | -$14.90M derived: 10-K 12 month − 10-Q 9 month · filed 2019-11-27 | -$4.57M 10-K · filed 2019-11-27 | ||
| 2017-06-30 | $10.33M 10-Q · filed 2018-08-09 | |||
| 2016-09-30 | -$43.66M 10-K · filed 2018-11-29 | |||
| 2014-03-31 | $17.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-05-12 | $18.60M 10-Q · filed 2014-05-12 | $10.96M derived: sum of 3 quarters · filed 2014-05-12 | -$37.26M derived: sum of 4 quarters · filed 2014-05-12 |
| 2013-12-31 | $1.35M 10-Q · filed 2014-02-13 | -$6.29M derived: sum of 2 quarters · filed 2014-02-13 | -$54.51M derived: sum of 3 quarters · filed 2014-02-13 | -$70.37M derived: sum of 4 quarters · filed 2014-05-12 |
| 2013-09-30 | -$7.64M derived: 10-K 12 month − 10-Q 9 month · filed 2013-12-18 | -$55.86M derived: sum of 2 quarters · filed 2013-12-18 | -$71.72M derived: sum of 3 quarters · filed 2014-05-12 | -$69.22M 10-K · filed 2013-12-18 |
| 2013-06-30 | -$48.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-08-12 | -$64.08M derived: sum of 2 quarters · filed 2014-05-12 | -$61.58M 10-Q · filed 2013-08-12 | -$52.34M derived: sum of 4 quarters · filed 2014-05-12 |
| 2013-03-31 | -$15.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-05-12 | -$13.36M 10-Q · filed 2014-05-12 | -$4.12M derived: sum of 3 quarters · filed 2014-05-12 | -$17.00M derived: sum of 4 quarters · filed 2014-05-12 |
| 2012-12-31 | $2.50M 10-Q · filed 2014-02-13 | $11.74M derived: sum of 2 quarters · filed 2014-02-13 | -$1.15M derived: sum of 3 quarters · filed 2014-02-13 | |
| 2012-09-30 | $9.24M derived: 10-K 12 month − 10-Q 9 month · filed 2013-12-18 | -$3.65M derived: sum of 2 quarters · filed 2013-12-18 | -$18.04M 10-K · filed 2013-12-18 | |
| 2012-06-30 | -$12.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-08-12 | -$27.28M 10-Q · filed 2013-08-12 | ||
| 2012-03-31 | -$14.39M 10-Q · filed 2013-05-15 | |||
| 2011-09-30 | -$17.68M 10-K · filed 2013-12-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |